Evidence map›Paper›PMID 33037272›Full record

ArticleScientific reports2020

Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease.

Emilie Hollville, Valerie Joers, Ayumi Nakamura, Vijay Swahari, Malú G Tansey, Sheryl S Moy, Mohanish Deshmukh

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Phosphatase Signaling as a Therapeutic Strategy in Schizophrenia.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Emilie HollvilleNeuroscience Center, University of North Carolina, Chapel Hill, NC, USA. hollville@unc.edu.
Valerie JoersDepartment of Neuroscience, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA.
Ayumi NakamuraNeuroscience Center, University of North Carolina, Chapel Hill, NC, USA.
Vijay SwahariNeuroscience Center, University of North Carolina, Chapel Hill, NC, USA.
Malú G TanseyDepartment of Neuroscience, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA.
Sheryl S MoyDepartment of Psychiatry, University of North Carolina, Chapel Hill, NC, USA.
Mohanish DeshmukhNeuroscience Center, University of North Carolina, Chapel Hill, NC, USA. mohanish@med.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Florida · US

Funding

UNC Neuroscience Center Research Cores: MicroscopyP30NS045892 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZYLKA, MARK J. · 2003 to 2022
$11.5M
Preclinical CoreU54HD079124 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BELGER, AYSENIL · 2013 to 2019
$8.0M
TRAINING IN TRANSLATIONAL RESEARCH IN NEUROLOGYT32NS007480 · NINDS · EMORY UNIVERSITY · PI LEVEY, ALLAN I · 2000 to 2020
$4.5M
Inflammation and Renin-Angiotensin System Dysfunction as risk factors for ADRF1AG051514 · NIA · EMORY UNIVERSITY · PI NORRIS, CHRISTOPHER MARK, WALKER, LARY C · 2015 to 2017
$3.6M
Establishing Apoptotic Thresholds: Insights from Neurons and Stem Cells to CancerR35GM118331 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESHMUKH, MOHANISH P · 2016 to 2020
$2.2M
Role of HLA/MHCII in Parkinson's Disease PathogenesisR01NS092122 · NINDS · EMORY UNIVERSITY · PI BOSS, JEREMY M., TANSEY, MARIA DE LOURDES GAMEZ · 2015 to 2019
$1.8M
Role of Gut Inflammation and Immunity on Proteostasis, Noradrenergic Degeneration and AD riskRF1AG057247 · NIA · UNIVERSITY OF FLORIDA · PI NEISH, ANDREW S, TANSEY, MARIA DE LOURDES GAMEZ · 2017 to 2017
$1.6M
NIA NIH HHS AG057247NIA NIH HHS RF1 AG051514NIA NIH HHS RF1 AG057247NICHD NIH HHS U54 HD079124NICHD NIH HHS U54-HD079124NIGMS NIH HHS GM118331NIGMS NIH HHS R35 GM118331NIH HHS T32NS007480NINDS NIH HHS NS092122NINDS NIH HHS P30 NS045892NINDS NIH HHS R01 NS092122NINDS NIH HHS T32 NS007480
6 · The paper itself

Abstract

Mitochondrial quality control is essential for the long-term survival of postmitotic neurons. The E3 ubiquitin ligase Parkin promotes the degradation of damaged mitochondria via mitophagy and mutations in Parkin are a major cause of early-onset Parkinson's disease (PD). Surprisingly however, mice deleted for Parkin alone are rather asymptomatic for PD-related pathology, suggesting that other complementary or redundant mitochondrial quality control pathways may exist in neurons. Mitochondrial damage is often accompanied by the release of toxic proteins such as cytochrome c. We have reported that once in the cytosol, cytochrome c is targeted for degradation by the E3 ligase CUL9 in neurons. Here we examined whether CUL9 and Parkin cooperate to promote optimal neuronal survival in vivo. We generated mice deficient for both Cul9 and Parkin and examined them for PD-related phenotypes. Specifically, we conducted assays to examine behavioural deficits (locomotor, sensory, memory and learning) and loss of dopaminergic neurons in both males and females. Our results show that the loss of Cul9 and Parkin together did not enhance the effect of Parkin deficiency alone. These results indicate that while both Parkin and CUL9 participate in mitochondrial quality control, neurons likely have multiple redundant mechanisms to ensure their long-term survival.

Indexed as

AnimalsDisease Models, AnimalDopaminergic NeuronsFemaleMaleMiceMice, KnockoutMitochondriaMitophagyMutationParkinson DiseaseTransferasesUbiquitin-Protein LigasesCul9 protein, humanparkin proteinTransferasesUbiquitin-Protein Ligases

Identifiers

PMID33037272
PMCPMC7547682
OpenAlexW3092336754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.